Valid indications of a key role for dopaminergic drugs in glycoprotein fucosylation in neuronal tissue in vitro led us to investigate whether the administration of dopaminergic agonists/antagonists influences fucose metabolism in the rat brain in vivo. Three test groups were set up. Group 1 was given L-DOPA (210 mg/1), Group 2 haloperidol (10.5 mg/1) in drinking water, Group 3 served as control. The rats were sacrificed after 8 weeks and enzyme activities in 5 different brain areas were determined concerning the enzymes of the anabolic fucose metabolism: fucokinase, fucose-1-phosphate pyrophosphorylase and fucosyltransferase 1 and 2. Only the specific activity of fucokinase was affected by haloperidol or L-DOPA administration. In the olfactory bulbus, thalamus and cortex, haloperidol decreased fucokinase activity by 21%, 37%, and 39%, respectively (p < 0.05 in each case). No changes were observed in the cerebellum and striatum. Surprisingly, fucokinase activity in the cortex was decreased by L-DOPA (31%, p < 0.05).
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Materials and Methods

Materials
Unless otherwise stated, all reagents were of analytical grade and were purchased from Merck (Darmstadt, Germany) and Sigma (M nchen, Germany). [ 
Enzyme assays
Fucokinase assay
Enzyme activity was determined as described earlier (11) . Briefly, the tissue was homogenized in nine volumes of assay buffer using a Dounce homogenizer, and the homogenate thus obtained was centrifuged at 40000g for 30 min. The supernatant served as a crude enzyme source for the fucokinase (and for fucose-1-phosphate pyrophosphorylase as well). The reaction mixture contained (in a final volume of 0.15 ml) 5 g/1 Triton X-100, 30 mmol/1 MgCl 2 , 10 mmol/1 phosphoenolpyruvate, pH 7.0,10 mmol/1 ATP, pH 7.0, 0.5 U of pyruvate kinase, 50 mmol/1 Tris-HCl, pH 7.4, 30 mmol/1 NaCl, 20 mmol/1 Lfucose and 0.4 mol/1 [ l4 C]L-fucose. The assay was started by addition of the crude enzyme preparation; after incubation of 37 °C for 20 min, the reaction was stopped by addition of cold ethanol (970 ml/1). After centrifugation at 20 000 g for 10 min, an aliquot of the resulting supernatant was applied to Whatman 3 MM paper, and the different fucose metabolites formed were separated by using the following solvent system: n-propanol/ Na(CH 3 COO), 1 mol/l/H 2 O (7 + 1 + 1, by vol.) according to Levin & Wei(\2) .
Fucose-1-phosphate pyrophosphorylase assay
The assay mixture contained (in a final volume of 0.1 ml) 100 mmol/1 Tris-HCl, pH 7.4, 5 mmol/1 MgCl 2 , 40 mmol/1 nicotinic acid, 10 g/1 Triton X-100, 10 mmol/1 GTP, 10 mmol/1 fueose-1-phosphate, and 0.8 μηιοΐ/ΐ L-[l- 14 C]fucose-l-phosphate. The reaction was started by addition of the crude enzyme preparation (as described above). After incubation for 20 min at 37 °C, the reaction was stopped by addition of cold ethanol (970 ml/1). After centrifugation at 20 000 g for 10 min, the supernatant was analyzed by paper chromatography using the following solvent system: C 2 H 5 OH/NH 3 (CH 3 COO), 1 mol/1 (5 + 2, by vol.) (13) .
Fucosyltransferase assay
The activity of the GDP-fucose : glycoprotein fucosyltransferases was determined by measuring the incorporation rate of [ ]fucose, 5 mmol/1 GDP-L-fucose, 0.5 mg acceptor (desialylated fetuin or desialodegalactofetuin), 1.5 g/1 Triton X-100 and 0.1 mg of sample protein from the homogenate before it was subjected to centrifugation (see above). The reaction mixture was incubated for 60 min at 37 °C and pipetted onto filter paper discs that had been mounted on pins. The discs were air-dried and washed twice for 30 min each with 100 g/1, with 50 g/1 trichloroacetic acid and then with ethanol/water, volume fraction 0.5 (14, 15) . Radioactivity was determined by counting the discs in a toluene scintillation mixture.
Animals
The investigation was performed using male Wistar rats weighing 200 g. Three test groups were set up. Group 1 was given L-DOPA (210 mg/1), Group 2 haloperidol (10.5 mg/1) in drinking water, while Group 3 served as control. Drinking water was changed every 2 hours to prevent breakdown of the drugs. After 8 weeks the rats were sacrificed, and the enzymatic activity of fucokinase, fucose-1-phosphate pyrophosphorylase and GDP-fucose as well as of glycoprotein fucosyltransferases, were determined in 5 different areas (olfactory bulbus, striatum, thalamus, cerebellum and cortex) carefully dissected from the total brain.
Statistics
All data are reported as χ ± SD and were analysed using Student's t-test.
Results
Rats treated with haloperidol or L-DOPA showed no weight loss as compared to controls. Enzyme activity differed considerably in the various brain areas of untreated control rats (figs 2-5). Fucose-1-phosphate pyrophosphorylase activity increased as follows: thal-amus < olfactory bulbus = cortex < striatum = cerebellum ( fig. 3) . Fucosyltransferase l activity, on the other hand, was quite similar in the different areas of the rat brain ( fig. 4) was clearly elevated in the cerebellum and nearly equal in the olfactory bulbus, striatum, thalamus and cortex ( fig. 5 ). Fucokinase activity increased in untreated rats as follows: thalamus < striatum < olfactory bulbus = cerebellum = cortex. fig. 2) in the olfactory bulbus, thalamus and cortex by 21%, 37%, and 39% respectively (p < 0.05 in each case). A decrease' of fucokinase activity in the cortex was also seen with L-DOPA (31%, p <0.05).
Direct addition of dopaminergic agonists/antagonists (L-DOPA, dopamine or haloperidol, 1 mmol/1 in each case) to the enzyme assays did not alter the enzymatic activity in vitro (tab. 1).
Discussion
Fucosylated glycoproteins in the rat brain seem to play an essential role in memory formation (3, 8, 9 ). GDP-fucose as a substrate for the different fucosyltransferases is mainly synthesized from L-fucose via the fucokinase and fucose-1-phosphate pyrophosphorylase reaction. According to our present data, the de novo synthesis of L-fucose starting from the precursor fructose-6-phosphate seems to be of minor importance in the rat brain, as the activity of the enzyme involved in the conversion of GDP-mannose via GDP-4-keto-6-deoxymannose to GDP-fucose was less than 5% compared to the activity of fucokinase or fucose-1-phosphate pyrophosphorylase in the rat brain in vivo (unpublished data from Prof. Dr. Ch. Bauer, Berlin). Fucosylation is influenced in vitro by dopaminergic drugs (10, 16, 17) . Our data clearly demonstrate for the first time that the activity of cerebral fucokinase, but not of fucose-1-phosphate pyrophosphorylase and GDP-fucose : glycoprotein fucosyltransferase, is influenced in vivo by haloperidol (dopaminergic receptor antagonist) in well-circumscribed brain areas (figs. 2-5). Cerebral fucokinase, therefore, may be the target enzyme of dopaminergic drugs that regulate or modulate fucosylation of glycoproteins in the rat brain in vivo. In our study we have measured enzyme activity. Therefore, a decrease in the amount of fucokinase or inhibition of fucokinase activity may explain our results. The intracellular mechanisms mediating the dopaminergic receptor agonists induced by incorporation of fucose are poorly understood. It has been shown that glycoprotein fucosylation can be stimulated in vitro by dibutyrylcAMP (14, 17) and phorbol esters (18) . However, direct addition of dopaminergic agonists (L-DOPA or dopamine) and dopaminergic antagonists (haloperidol) to the enzyme assays did not alter the enzymatic activity (tab. 1). Interaction of drugs with glycoprotein metabolism is well known, e. g. the significant upregulation of liver ß-galactoside a2,6-sialyltransferase by glucocorticoids (20) . However, in our study fucosyltransferase activity is not altered; we observed drug-mediated significant changes only in rat brain fucokinase activity. So far at least four different fucosyltransferases are known, mainly determined in rat liver. In the brain up to now only one subtype of fucosyltransferase (a-1-3 fucosyltransferase) has been demonstrated (21, 22) .
The unexpected finding that L-DOPA (decarboxylated in vivo to dopamine) decreases fucokinase activity (cortex, fig. 2 ) or has no effect (olfactory bulbus, striatum, thalamus and cerebellum) may be due to a receptor downregulation by receptor agonists. The opposite effect (upregulation of dopaminergic receptors) was seen after chronic treatment of rats with dopamine receptor antagonists (19) .
